|
Market Closed -
Nasdaq
16:00:00 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 28.84 USD | -9.02% |
|
-12.15% | - |
| 08-24 | Top Premarket Gainers | MT |
| 08-18 | Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target | MT |
| Market Cap | 544M 467M 437M 400M 754M 51.96B 756M 5.18B 2.02B 26.19B 2.04B 2B 86.67B | P/E 2026 * |
-5.06x | P/E 2027 * | -6.34x |
|---|---|---|---|---|---|
| Enterprise Value | 440M 378M 354M 324M 610M 42.03B 612M 4.19B 1.64B 21.19B 1.65B 1.62B 70.11B | EV / Sales 2026 * |
38.1x | EV / Sales 2027 * | 62x |
| Free-Float |
-
| Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -9.02% | ||
| 1 week | -12.15% | ||
| Current month | +48.05% | ||
| 1 month | +52.03% |
| 1 week | 27.54 |  | 38.9 |
| 1 month | 17.8 | | 39.6 |
| Current year | 17.3 | | 39.6 |
| 1 year | 17.3 | | 39.6 |
| 3 years | 17.3 | | 39.6 |
| 5 years | 17.3 | | 39.6 |
| 10 years | 17.3 | | 39.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brett Staahl
PRN | Corporate Officer/Principal | - | - |
Benjamin Oakes
CEO | Chief Executive Officer | 37 | 2017-05-31 |
David Parrot
DFI | Director of Finance/CFO | 57 | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Benjamin Oakes
BRD | Director/Board Member | 37 | 2017-05-31 |
Behzad Aghazadeh
BRD | Director/Board Member | 54 | 2021-02-28 |
James Watson
BRD | Director/Board Member | 60 | 2025-06-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/28/26 | Avoro Capital Advisor LLC
| Buy | Company | 7,905 | - | |
| 7/27/26 | OrbiMed Advisors Private Equity
| Conversion | Company | 3,414,497 | - | |
| 7/27/26 | a16z Capital Management LLC
| Conversion | Company | 19,364,072 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.02% | -12.15% | - | - | 598M | |
| +0.10% | +0.44% | +2.80% | +24.32% | 50.96B | |
| +2.65% | +4.45% | +481.36% | +567.32% | 46.18B | |
| -0.88% | +0.90% | +24.11% | +87.74% | 42.73B | |
| +0.33% | +2.47% | +38.97% | +19.80% | 43.04B | |
| -2.27% | -3.02% | +14.22% | +51.50% | 33.48B | |
| -1.21% | -0.17% | +29.16% | +135.38% | 17.28B | |
| -0.36% | -2.14% | - | - | 16.43B | |
| +0.25% | +0.25% | +12.03% | +30.68% | 14.73B | |
| +0.44% | +1.70% | +82.07% | +47.92% | 14.09B | |
| Average | -1.00% | -0.91% | +85.59% | +120.58% | 27.95B | |
| Weighted average by Cap. | +0.02% | +0.54% | +104.35% | +141.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.55M 9.91M 9.28M 8.5M 16.01M 1.1B 16.05M 110M 42.96M 556M 43.36M 42.42M 1.84B | 6.74M 5.78M 5.41M 4.96M 9.34M 643M 9.37M 64.12M 25.06M 324M 25.3M 24.75M 1.07B |
| Net income | -76.4M -65.58M -61.4M -56.22M -106M -7.3B -106M -727M -284M -3.68B -287M -281M -12.17B | -93.23M -80.03M -74.93M -68.61M -129M -8.9B -130M -887M -347M -4.49B -350M -342M -14.85B |
| Net Debt | -104M -89.21M -83.52M -76.48M -144M -9.93B -144M -989M -387M -5B -390M -382M -16.56B | -126M -108M -101M -92.93M -175M -12.06B -176M -1.2B -470M -6.08B -474M -464M -20.12B |
Employees
89
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-27 | US$28.84 | -9.02% | 194,825 |
| 26-08-26 | US$31.70 | +1.59% | 246,288 |
| 26-08-25 | US$31.21 | -16.23% | 316,029 |
| 26-08-24 | US$37.25 | +9.14% | 545,547 |
| 26-08-21 | US$34.13 | +3.96% | 179,577 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
28.84USD
Average target price
56.00USD
Spread / Average Target
+94.17%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SCTX Stock
Select your edition
All financial news and data tailored to specific country editions
